Feature | August 30, 2011

Low-Risk Patients Fare the Same With Transcatheter Aortic Valve vs. Surgery

August 30, 2011 – Results from a study presented at the European Society of Cardiology (ESC) Congress 2011 show that transcatheter aortic-valve implantation (TAVI) in low-risk patients met with 100 percent procedural success (versus 95.3 percent in the high Euroscore group (p=0.1). While researchers expected a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated.  In fact, the mortality rates with the Edwards Sapien valve have approached the results with conventional surgery.

The results represent a first step towards a broader assessment of percutaneous techniques in populations at lower surgical risk but without forgetting that surgery is currently the gold standard, said Matthieu Godin, M.D., from the University Hospital of Rouen, France.

“The most interesting point to observe is the absence of death at one month in the low Euroscore group, versus a mortality rate of 11.1 percent in the high Euroscore group (>20 percent), (p < 0.04) and this result is confirmed at one-year with 5 versus 24.8 percent, (p<0.01). While we were expecting a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated. In fact, the mortality rates have approached the results with conventional surgery,” Godin said.

Aortic stenosis is the most frequently acquired valve disease in adults. Two percent are symptomatic and thus should require aortic valve replacement because, in this disease, a long latency is followed by rapid progression after the appearance of symptoms, with more than half of patients dying within two years. It can be estimated that with the aging population, within 15 years, the number of aortic stenosis patients will double.

After more than 15 years of research, the first-in-man percutaneous valve implantation was performed in the center at the University Hospital of Rouen by Alain Cribier in April 2002. Since then, about 40,000 patients have been implanted worldwide with the use of two different models of valve: the balloon expandable valve and the self-expanding device. The CE mark was obtained for both in 2007. TAVI can today be proposed as an alternative treatment and has recently demonstrated its great efficiency with the results of the pivotal PARTNER-US trial. 
 
Based on the recommendations of both the ESC and the European Society of Cardiac Surgery, most of the registries have so far only included patients with high logistic Euroscore > 20 percent (a system developed to predict the operative mortality of coronary surgery).

In view of the overall good results in this high-risk population, a significant trend to include lower risk patients in Europe has been observed. The last registries have seen their Euroscore decreasing to 15 percent and some prospective trials are planned to include patients whatever their score.

“We sought to evaluate the results obtained in our subgroup of patients with a low Euroscore. It does not mean that the patients were at very low risk for TAVI, since they had been considered as having surgical contraindication, which did not affect the Euroscore (radiotherapy, corticosteroids, thoracic deformation or porcelain aorta). However, the patients were often less sick and younger and it seemed interesting to assess the results in this population,” said Godin.

This study is a retrospective study from all 177 patients implanted with the Edwards prosthesis at the Rouen center between May 2006 and January 2011. Patients were divided into two groups according to their predictive Logistic Euroscore: High Euroscore (>20 percent) vs Low Euroscore (<20 percent).

For more information: www.escardio.org

Related Content

News | Stem Cell Therapies| May 26, 2016
May 26, 2016 — Ligand Pharmaceuticals Inc.
Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016
News | Heart Valve Technology| May 24, 2016
Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve...
CardiAQ, Neovasc, lawsuit, TMVR
News | Business| May 24, 2016
Edwards Lifesciences Corp. announced that a federal jury in Boston returned a verdict in favor of CardiAQ in a lawsuit...
Mitralign, Series E funding, Trialign, MPAS
News | Heart Valve Technology| May 23, 2016
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting
News | Heart Valve Technology| May 18, 2016
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic...
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
4Tech Inc., TriCinch transcatheter tricuspid valve repair device, Jean-Claude Laborde

Image courtesy of 4Tech Inc.

News | Heart Valve Technology| May 16, 2016
4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and...
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart| May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
Overlay Init